Biofortuna Ltd appoints new chairman to lead next phase of growth

26-Feb-2015 - United Kingdom

Biofortuna has appointed a new chairman to lead the next phase of growth.  Life sciences expert Ian Johnson will take on the role at Biofortuna with previous chairman Mark Hurley remaining on the board as a non-executive director.

Ian has spent his business career in life sciences. He was founder and CEO of Biotrace International plc, a leading provider of rapid microbial testing systems and reagents, which was sold to 3M for $100M. Ian is currently non-executive chairman of Celsis Group Ltd and Cyprotex PLC, both Harwood Private Equity investments, a company for which Ian acts as an operational advisor.  Ian has served on the boards of various public and private companies in strategic consultancy and business development capacities, including Evans Analytical Group, MyCelx Technologies Corporation and AOI Medical Inc.

Other news from the department people

Most read news

More news from our other portals

So close that even
molecules turn red...